English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT03314181 /

M15-654

A Phase 1/2, Multicenter, Dose-Escalation And Expansion Study Of Combination Therapy With Venetoclax, Daratumumab And Dexamethasone (With And Without Bortezomib) In Subjects With Relapsed Or Refractory Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: